Scott Lieberman

Dr. Scott Lieberman

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SLScott Lieberman
Scott Lieberman
AEAnne M. Evans
Anne M. Evans
BHBingye Han
Bingye Han
TTToshiyuki Takaki
Toshiyuki Takaki
YVYuliya Vinnitskaya
Yuliya Vinnitskaya
TDTeresa P. DiLorenzo
Teresa P. DiLorenzo
Type 1 diabetes is an autoimmune disease in which autoreactive T cells attack and destroy the insulin-producing pancreatic β cells. CD8+T cells are essential for this β cell destruction, yet their specific antigenic targets are largely unknown. Here, we reveal that the autoantigen targeted by a prevalent population of pathogenic CD8+T cells in nonobese diabetic mice is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Through tetramer technology, IGRP-reactive T cells are readily detected in islets and peripheral blood directlyex vivo. The human IGRP gene maps to a diabetes susceptibility locus, suggesting that IGRP also may be an antigen for pathogenic T cells in human type 1 diabetes and, thus, a new, potential target for diagnostic and therapeutic approaches.

8 August 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
DFDeLisa Fairweather
DeLisa Fairweather
DBDanielle J. Beetler
Danielle J. Beetler
EMElizabeth J. McCabe
Elizabeth J. McCabe
SLScott Lieberman
Scott Lieberman
Autoimmune diseases are a leading cause of disability worldwide. Most autoimmune diseases occur more often in women than men, with rheumatic autoimmune diseases being among those most highly expressed in women. Several key factors, identified mainly in animal models and cell culture experiments, are important in increasing autoimmune disease in females. These include sex hormones, immune genes including those found on the X chromosome, sex-specific epigenetic effects on genes by estrogen and the environment, and regulation of genes and messenger RNA by microRNAs found in extracellular vesicles. Evidence is also emerging that viruses as well as drugs or toxins that damage mitochondria may contribute to increased levels of autoantibodies against nuclear and mitochondrial antigens, which are common in many autoimmune diseases. The purpose of this Review is to summarize our current understanding of mechanisms that may determine sex differences in autoimmune disease.

13 October 2003 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
SLScott Lieberman
Scott Lieberman
TDT.P. DiLorenzo
T.P. DiLorenzo

1 December 2004 in The Journal of Immunology
Verified
Journal Article
Closed access
SLScott Lieberman
Scott Lieberman
TTToshiyuki Takaki
Toshiyuki Takaki
BHBingye Han
Bingye Han
PSPere Santamaria
Pere Santamaria
DSDavid V Serreze
David V Serreze
TDTeresa P DiLorenzo
Teresa P DiLorenzo
Spontaneous autoimmune diabetes development in NOD mice requires both CD8+ and CD4+ T cells. Three pathogenic CD8+ T cell populations (represented by the G9C8, 8.3, and AI4 clones) have been described. Although the Ags for G9C8 and 8.3 are known to be insulin and islet-specific glucose-6-phosphatase catalytic subunit-related protein, respectively, only mimotope peptides had previously been identified for AI4. In this study, we used peptide/MHC tetramers to detect and quantify these three pathogenic populations among β cell-reactive T cells cultured from islets of individual NOD mice. Even within age-matched groups, each individual mouse exhibited a unique distribution of β cell-reactive CD8+ T cells, both in terms of the number of tetramer-staining populations and the relative proportion of each population in the islet infiltrate. Thus, the inflammatory process in each individual follows its own distinctive course. Screening of a combinatorial peptide library in positional scanning format led to the identification of a peptide derived from dystrophia myotonica kinase (DMK) that is recognized by AI4-like T cells. Importantly, the antigenic peptide is naturally processed and presented by DMK-transfected cells. DMK is a widely expressed protein that is nonetheless the target of a β cell-specific autoimmune response.

23 May 2017 in Immunology & Cell Biology
Verified
Journal Article
Open access
PDF file
JBJennifer Y Barr
Jennifer Y Barr
XWXiaofang Wang
Xiaofang Wang
DMDavid K. Meyerholz
David K. Meyerholz
SLScott Lieberman
Scott Lieberman
Sjögren syndrome is an autoimmune disease characterized by targeted destruction of the lacrimal and salivary glands resulting in symptoms of severe ocular and oral dryness. Despite its prevalence, the mechanisms driving autoimmune manifestations are unclear. In patients and in the nonobese diabetic (NOD) mouse model of Sjögren syndrome, lymphocytic infiltrates consist of CD4 and CD8 T cells, although the role of CD8 T cells in disease pathogenesis has been largely unexplored. Here, we evaluated the contribution of CD8 T cells to lacrimal and salivary gland autoimmunity. Within the lacrimal and salivary glands of NOD mice, CD8 T cells were proliferating, expressed an activated phenotype, and produced inflammatory cytokines. Transfer of purified CD8 T cells isolated from the cervical lymph nodes (LNs) of NOD mice into NOD‐severe combined immunodeficiency recipients resulted in inflammation of the lacrimal glands, but was not sufficient to cause inflammation of the salivary glands. Lacrimal gland‐infiltrating CD8 T cells displayed a cytotoxic phenotype, and epithelial cell damage in the lacrimal glands was observed in recipients of CD8 T cells regardless of the presence of CD4 T cells. Collectively, our results demonstrate that CD8 T cells have a pathogenic role in lacrimal gland autoimmunity. The gland‐specific pathogenicity of CD8 T cells makes them a valuable resource to further understand the mechanisms that discriminate lacrimal versus salivary gland autoimmunity and for the development of new therapeutics that target the early stages of disease.

1 December 2002 in Clinical Immunology
Verified
Journal Article
Closed access
TDTeresa P. DiLorenzo
Teresa P. DiLorenzo
SLScott Lieberman
Scott Lieberman
TTToshiyuki Takakia
Toshiyuki Takakia
SHShinichiro Honda
Shinichiro Honda
HCHarold D. Chapman
Harold D. Chapman
SNStanley G. Nathenson
Stanley G. Nathenson